FDA Approves Moderna's Second-Ever Product: RSV Vaccine for Seniors
TL;DR Summary
The FDA has approved Moderna's RSV vaccine, mRESVIA, for adults aged 60 and above, marking the company's second product to enter the U.S. market. This approval is crucial for Moderna as it seeks new revenue sources amid declining demand for its Covid vaccine. The mRNA-based RSV vaccine, which is the first of its kind for a disease other than Covid, showed 83.7% efficacy in a late-stage trial. The CDC will vote on usage recommendations in June, potentially allowing Moderna to compete with existing RSV vaccines from GSK and Pfizer.
- FDA approves Moderna's RSV vaccine for seniors, the company's second-ever product CNBC
- FDA approves Moderna’s mRNA RSV vaccine The Hill
- FDA approves Moderna's RSV vaccine, its second licensed product STAT
- Moderna's RSV vaccine gets FDA approval The Boston Globe
- US FDA approves Moderna's RSV vaccine, its second marketed product Reuters
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
3 min
vs 4 min read
Condensed
86%
657 → 89 words
Want the full story? Read the original article
Read on CNBC